VαMPiRE, funded by the EU, aims to develop the first simple, early diagnostic test for Parkinson’s disease by identifying new α-synuclein biomarkers in 1,200 participants. A major step toward earlier detection and better care. The project includes 13 EU partners and one in Australia.